Topical antiandrogens (hair)
Clascoterone vs Pyrilutamide vs RU58841
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
 Clascoterone |  Pyrilutamide | RU58841 | |
|---|---|---|---|
| What it is | Cortexolone 17α-propionate (CB-03-01): the first FDA-approved TOPICAL androgen-receptor antagonist. Approved for acne (Winlevi 1% cream, 2020); in investigational phase for androgenetic alopecia (Breezula solution). Acts locally and is rapidly inactivated systemically. | Pyrilutamide (KX-826) – a topical androgen-receptor antagonist developed by Kintor for androgenetic alopecia (and acne). INVESTIGATIONAL compound: in phase 2/3 trials (China/US), not approved anywhere, peer-reviewed efficacy data still sparse. | Nonsteroidal topical androgen-receptor antagonist (PSK-3841), developed by Roussel-Uclaf in the 1980s. NEVER licensed; only ANIMAL data + grey-market anecdote exist, with NO completed human clinical trial. Experimental, unproven and unverified. |
| Development code / name | CB-03-01 · cortexolone 17α-propionate | — | — |
| Status | Acne: FDA-approved (Winlevi) · Hair (AGA): phase 3 investigational | INVESTIGATIONAL – phase 2/3 (AGA); not approved anywhere | EXPERIMENTAL – never licensed; no completed human trial |
| Mechanism of actionMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | Topical androgen-receptor antagonist (local anti-DHT) | Topical androgen-receptor antagonist (local anti-DHT) | Nonsteroidal topical androgen-receptor antagonist (local anti-DHT) |
| Strengths | 1% cream (acne) · 5-7.5% solution (investigational AGA) | — | — |
| OnsetOnsetThe time from dosing until a measurable effect appears. | 4-12 weeks (acne); hair: months, during phase 3 | — | — |
| Development code | — | KX-826 (Kintor Pharmaceutical) | — |
| Form studied | — | Topical solution (e.g. 0.5% / 1.0%, 1-2x daily) | — |
| Evidence | — | Early/mid-phase; published efficacy still lacking | ONLY animal/preclinical + anecdote – NO human data |
| Other code | — | — | PSK-3841 · RU-58841 (Roussel-Uclaf) |
| Access | — | — | Not available as a drug; only unverified grey market |
| Full entry | Open → | Open → | Open → |
What it is
ClascoteroneCortexolone 17α-propionate (CB-03-01): the first FDA-approved TOPICAL androgen-receptor antagonist. Approved for acne (Winlevi 1% cream, 2020); in investigational phase for androgenetic alopecia (Breezula solution). Acts locally and is rapidly inactivated systemically.
PyrilutamidePyrilutamide (KX-826) – a topical androgen-receptor antagonist developed by Kintor for androgenetic alopecia (and acne). INVESTIGATIONAL compound: in phase 2/3 trials (China/US), not approved anywhere, peer-reviewed efficacy data still sparse.
RU58841Nonsteroidal topical androgen-receptor antagonist (PSK-3841), developed by Roussel-Uclaf in the 1980s. NEVER licensed; only ANIMAL data + grey-market anecdote exist, with NO completed human clinical trial. Experimental, unproven and unverified.
Development code / name
ClascoteroneCB-03-01 · cortexolone 17α-propionate
Pyrilutamide—
RU58841—
Status
ClascoteroneAcne: FDA-approved (Winlevi) · Hair (AGA): phase 3 investigational
PyrilutamideINVESTIGATIONAL – phase 2/3 (AGA); not approved anywhere
RU58841EXPERIMENTAL – never licensed; no completed human trial
Mechanism of actionMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds).
ClascoteroneTopical androgen-receptor antagonist (local anti-DHT)
PyrilutamideTopical androgen-receptor antagonist (local anti-DHT)
RU58841Nonsteroidal topical androgen-receptor antagonist (local anti-DHT)
Strengths
Clascoterone1% cream (acne) · 5-7.5% solution (investigational AGA)
Pyrilutamide—
RU58841—
OnsetOnsetThe time from dosing until a measurable effect appears.
Clascoterone4-12 weeks (acne); hair: months, during phase 3
Pyrilutamide—
RU58841—
Development code
Clascoterone—
PyrilutamideKX-826 (Kintor Pharmaceutical)
RU58841—
Form studied
Clascoterone—
PyrilutamideTopical solution (e.g. 0.5% / 1.0%, 1-2x daily)
RU58841—
Evidence
Clascoterone—
PyrilutamideEarly/mid-phase; published efficacy still lacking
RU58841ONLY animal/preclinical + anecdote – NO human data
Other code
Clascoterone—
Pyrilutamide—
RU58841PSK-3841 · RU-58841 (Roussel-Uclaf)
Access
Clascoterone—
Pyrilutamide—
RU58841Not available as a drug; only unverified grey market